Quarterly ResultMay 6, 2026, 06:37 AM
United Therapeutics Q1 Net Income Down 14.7% to $274.9M; $1.5B Buyback
AI Summary
United Therapeutics reported a decline in Q1 2026 net income and revenues compared to the prior year. Net income decreased by 14.7% to $274.9 million, with total revenues falling 1.6% to $781.5 million. The company also initiated a significant capital return program, repurchasing $1.5 billion of common stock through accelerated share repurchase agreements. Additionally, the maturity date of the 2025 Credit Agreement was extended to April 2031, and the company recognized a $12.8 million gain from an investment in a privately held company.
Key Highlights
- Initiated $1.5 billion common stock repurchase via accelerated share repurchase agreements.
- Q1 2026 net income decreased 14.7% to $274.9 million from $322.2 million in Q1 2025.
- Total revenues for Q1 2026 were $781.5 million, a 1.6% decrease from $794.4 million in Q1 2025.
- Diluted EPS for Q1 2026 fell 12.2% to $5.82 from $6.63 in Q1 2025.
- Operating income for Q1 2026 decreased 14.9% to $325.8 million.
- Net cash provided by operating activities was $463.3 million in Q1 2026.
- Recognized a $12.8 million gain from an increased valuation of an investment in a privately held company.
- Extended the maturity date of the $2.5 billion 2025 Credit Agreement to April 2031.